Search the Newsreel

Soleus Capital group (VCEL) discloses 2.8% Vericel ownership under 5% level

Soleus Capital Master Fund, L.P. and associated entities have reported a beneficial ownership of 2.8% in Vericel Corp (VCEL) common stock, totaling 1,458,882 shares. This updated disclosure, filed on an amended Schedule 13G, places their ownership below the 5% threshold, indicating passive investment. All …

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MediWound Ltd. EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 …

Kevin McLaughlin (VCEL) to sell 7,000 shares after stock option exercise

Kevin McLaughlin, an insider at Vericel Corp (VCEL), has filed a notice of proposed sale for 7,000 shares of common stock. This sale is scheduled for on or after August 12, 2026, and is associated with a stock option exercise. McLaughlin previously sold 7,000 …

Vericel Corporation $VCEL Shares Sold by Kopp Family Office LLC

Kopp Family Office LLC significantly reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 68.7% in the second quarter, selling 112,302 shares and retaining 51,053 shares valued at approximately $2.27 million. Despite this, Vericel reported strong Q2 earnings, exceeding expectations with $0.04 EPS and $77.46 …

What Vericel (VCEL)'s Profit Turnaround, Higher Outlook and Buyback Plan Means For Shareholders

Vericel Corp (VCEL) Stock News Today

This article provides current stock information for Vericel Corp (VCEL), including its latest stock price, market cap, and P/E TTM. It notes that more news and updates for VCEL stock will be available soon. The page serves as a hub for news, analysis, financials, …

Vericel Corp (VCEL) COO exercises options, sells 10,000 shares

Vericel Corp's Chief Operating Officer, Michael Halpin, exercised stock options to acquire 10,000 shares at $16.66 per share and simultaneously sold these 10,000 shares at $46.84 per share on August 3, 2026. This transaction, executed under a Rule 10b5-1 trading plan established on December …

Q3 2025 Vericel Corp Earnings Call Transcript

Vericel Corp (FRA:ATQP) reported record Q3 2025 total revenue of $67.5 million, exceeding guidance, primarily driven by a 25% increase in Macy revenue and strong biopsy growth. The company achieved a GAAP net income over $5 million and an adjusted EBITDA margin of 25%, …

Form 144 Vericel Corp For: 3 August By Investing.com

This article from Investing.com announces the filing of Form 144 by Vericel Corp on August 3rd. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates plan to sell shares. The brief note provides the date of …

Vericel (VCEL) insider Michael Halpin files to sell 10,000 shares

Vericel Corporation insider Michael Halpin has filed to sell 10,000 shares of common stock, valued at $459,800.00, on August 3, 2026, through Fidelity Brokerage Services LLC. These shares are related to a stock option exercise on the same date. Halpin also previously sold 10,000 …

Vericel (VCEL) Stock Faces Valuation Scrutiny After Record Revenue Growth

Vericel Corp (VCEL) officer exercises options and sells 4,500 shares

Jonathan Siegal, Principal Accounting Officer at Vericel Corp (VCEL), exercised stock options for 4,500 shares and subsequently sold all 4,500 shares at $48.90 per share on July 30, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025. …

VERICEL CORP : LEERINK PARTNERS RAISES TARGET PRICE TO $59.00 FROM $46.00

LEERINK PARTNERS has increased its target price for VERICEL CORP (VCEL.O) to $59.00, up from the previous target of $46.00. This update reflects a significant change in the analyst's valuation of the company. The information was released by Reuters.

Vericel Q2 Earnings Call Highlights

Key Points Interested in Vericel Corporation? Here are five stocks we like better. Record Q2 performance: Vericel's revenue rose 22% year over year to $77.5 million, while GAAP net income reached $2.2 million and free cash flow totaled $14.3 million. Growth across franchises: MACI …

Earnings call transcript: Vericel tops Q2 2026 estimates, lifts outlook

Vericel Corporation (VCEL) reported second-quarter 2026 earnings and revenue that exceeded Wall Street estimates, driven by strong performance in its MACI cartilage repair and burn care businesses. The company raised its full-year 2026 revenue guidance to $330 million-$340 million and announced a $200 million …

Vericel (VCEL) insider files to sell 4,500 shares after option exercise

Vericel (VCEL) insider Jonathan Siegal filed a Form 144 to sell 4,500 shares of common stock, valued at an aggregate of $220,050.00, following a stock option exercise on July 30, 2026. The sale will be executed through Fidelity Brokerage Services LLC. This filing follows …

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This …

Vericel Corp Ord earnings beat by $0.07, revenue topped estimates

Vericel Corp Ord (NASDAQ: VCEL) reported second-quarter earnings per share of $0.04, exceeding analyst estimates by $0.07. The company's revenue of $77.45 million also surpassed the consensus estimate of $72.7 million. Vericel Corp Ord's stock has shown strong performance, rising over 31% in the …

Vericel Corp 2Q 2026: Revenue $77.46M, EPS $0.04— 10-Q Summary

Vericel Corp reported strong second-quarter 2026 results, with revenue rising 22.5% to $77.46M and diluted EPS reaching $0.04 compared to a loss in the prior year. The growth was attributed to increased MACI and Epicel volume, MACI Arthro expansion, and the approval of the …

Vericel Reports Q2 2026 Revenue Up 22% to $77.5M, Raises 2026 Guidance and Authorizes $200M Buyback

Vericel reported strong second-quarter 2026 results with total net revenue increasing 22% year-over-year to $77.5 million, driven by growth in MACI, Burn Care, and Epicel. The company raised its full-year 2026 revenue guidance to $330–$340 million and announced a $200 million share repurchase program, …

Vericel Corp (VCEL) Q2 2026 Earnings

Vericel Corp (VCEL) reported strong Q2 2026 earnings, swinging to profitability with an EPS of $0.04 against an estimated loss of $-0.03, and revenue of $77 million, surpassing estimates of $73 million. The company also announced a $200 million share buyback, indicating confidence in …

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

Vericel Corporation Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share …

VCEL|Vericel Corp|Price:46.560|Chg%:-0.150

This article provides a comprehensive stock analysis of Vericel Corp (VCEL) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis includes its stock score, key insights, analyst ratings (mostly "Buy" with a target price of …

H.C. Wainwright reiterates Vericel stock rating with $70 target

H.C. Wainwright has reiterated a Buy rating on Vericel Corporation (NASDAQ:VCEL) stock, setting a price target of $70.00. The company is set to report its second-quarter 2026 results soon, with strong guidance for MACI and Burn Care revenues indicating significant year-over-year growth. Vericel's recent …

Vericel Corporation (VCEL) Options Chain

This article provides detailed options chain data for Vericel Corporation (VCEL), including call and put options with various strike prices and expiration dates. It lists the last trade date, last price, bid, ask, volume, open interest, and implied volatility for each contract. Additionally, it …

Vericel Corp (VCEL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Vericel Corp (VCEL), highlighting major institutional investors like BlackRock, State Street, and Soleus Capital Management. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for top …

Vericel Corp (VCEL) Cash Flow

This article provides a detailed historical cash flow statement for Vericel Corp (VCEL), including operating, investing, and financing cash flows presented quarterly and annually. It features key financial metrics such as net income from continuing operations, capital expenditures, and free cash flow, along with …

Vericel Corp (VCEL) Income Statement

This article provides the quarterly and annual income statements for Vericel Corp (VCEL), offering detailed financial data ranging from total revenue to basic and diluted earnings per share. It highlights financial performance metrics and includes an FAQ section to guide users on how to …

Vericel Corp (VCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Vericel Corp (VCEL), highlighting its current earnings forecast score of 8.50 and an average price target of $55.00 from analysts. It includes details on analyst ratings, peer comparison, expected revenue, and past and future EPS performance. The …

VCEL|Vericel Corp|Price:45.050|Chg%:+0.005

Vericel Corp (VCEL) is a commercial-stage biopharmaceutical company specializing in advanced therapies for sports medicine and severe burn care. The company's stock is currently priced at $45.050, and its fundamentals are considered healthy with high growth potential, though its valuation is seen as fairly …

Vericel stock hits 52-week high at 48.41 USD

Vericel Corporation's stock has reached a 52-week high of $48.41, reflecting a significant increase of 30.58% over the past year and nearly 30% year-to-date. This milestone is supported by strong Q1 2026 financial results, where the company surpassed analyst expectations for both EPS and …

VCEL Maintained by Truist Securities -- Price Target Raised to $54.00

Truist Securities has reiterated its 'Buy' rating for Vericel (VCEL) and increased its price target to $54.00 from $42.00, suggesting a potential 28.57% upside from its current price. GuruFocus indicates VCEL is undervalued by 12.9% with a GF Value of $55.02 and a strong …

Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026

Vericel Corporation announced it will report its second-quarter 2026 financial results on Thursday, July 30, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and business highlights. Vericel specializes in advanced therapies for sports …